Drug Discovery Targeting Bromodomain-Containing Protein 4

Zhiqing Liu, Pingyuan Wang, Haiying Chen, Eric A. Wold, Bing Tian, Allan R. Brasier, Jia Zhou

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

BRD4, the most extensively studied member of the BET family, is an epigenetic regulator that localizes to DNA via binding to acetylated histones and controls the expression of therapeutically important gene regulatory networks through the recruitment of transcription factors to form mediator complexes, phosphorylating RNA polymerase II, and by its intrinsic histone acetyltransferase activity. Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine production in acute inflammation, and so forth. To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed to human clinical trials. Herein, we summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action, and therapeutic potential. Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.

Original languageEnglish (US)
Pages (from-to)4533-4558
Number of pages26
JournalJournal of Medicinal Chemistry
Volume60
Issue number11
DOIs
StatePublished - Jun 8 2017

Fingerprint

Drug Discovery
Drug Delivery Systems
Mediator Complex
Histone Acetyltransferases
RNA Polymerase II
Gene Regulatory Networks
Epigenomics
Histones
Action Potentials
Lysine
Proteins
Transcription Factors
Cell Proliferation
Clinical Trials
Cytokines
Inflammation
DNA
Therapeutics
Neoplasms
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Drug Discovery Targeting Bromodomain-Containing Protein 4. / Liu, Zhiqing; Wang, Pingyuan; Chen, Haiying; Wold, Eric A.; Tian, Bing; Brasier, Allan R.; Zhou, Jia.

In: Journal of Medicinal Chemistry, Vol. 60, No. 11, 08.06.2017, p. 4533-4558.

Research output: Contribution to journalReview article

Liu, Zhiqing ; Wang, Pingyuan ; Chen, Haiying ; Wold, Eric A. ; Tian, Bing ; Brasier, Allan R. ; Zhou, Jia. / Drug Discovery Targeting Bromodomain-Containing Protein 4. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 11. pp. 4533-4558.
@article{8af7423404974d7da565d365c249d1ed,
title = "Drug Discovery Targeting Bromodomain-Containing Protein 4",
abstract = "BRD4, the most extensively studied member of the BET family, is an epigenetic regulator that localizes to DNA via binding to acetylated histones and controls the expression of therapeutically important gene regulatory networks through the recruitment of transcription factors to form mediator complexes, phosphorylating RNA polymerase II, and by its intrinsic histone acetyltransferase activity. Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine production in acute inflammation, and so forth. To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed to human clinical trials. Herein, we summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action, and therapeutic potential. Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.",
author = "Zhiqing Liu and Pingyuan Wang and Haiying Chen and Wold, {Eric A.} and Bing Tian and Brasier, {Allan R.} and Jia Zhou",
year = "2017",
month = "6",
day = "8",
doi = "10.1021/acs.jmedchem.6b01761",
language = "English (US)",
volume = "60",
pages = "4533--4558",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Drug Discovery Targeting Bromodomain-Containing Protein 4

AU - Liu, Zhiqing

AU - Wang, Pingyuan

AU - Chen, Haiying

AU - Wold, Eric A.

AU - Tian, Bing

AU - Brasier, Allan R.

AU - Zhou, Jia

PY - 2017/6/8

Y1 - 2017/6/8

N2 - BRD4, the most extensively studied member of the BET family, is an epigenetic regulator that localizes to DNA via binding to acetylated histones and controls the expression of therapeutically important gene regulatory networks through the recruitment of transcription factors to form mediator complexes, phosphorylating RNA polymerase II, and by its intrinsic histone acetyltransferase activity. Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine production in acute inflammation, and so forth. To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed to human clinical trials. Herein, we summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action, and therapeutic potential. Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.

AB - BRD4, the most extensively studied member of the BET family, is an epigenetic regulator that localizes to DNA via binding to acetylated histones and controls the expression of therapeutically important gene regulatory networks through the recruitment of transcription factors to form mediator complexes, phosphorylating RNA polymerase II, and by its intrinsic histone acetyltransferase activity. Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine production in acute inflammation, and so forth. To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed to human clinical trials. Herein, we summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action, and therapeutic potential. Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.

UR - http://www.scopus.com/inward/record.url?scp=85020397055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020397055&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b01761

DO - 10.1021/acs.jmedchem.6b01761

M3 - Review article

C2 - 28195723

AN - SCOPUS:85020397055

VL - 60

SP - 4533

EP - 4558

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 11

ER -